Indian health care

Keeping it simple

Lucknow

If India's ambitious target of "health for all" by the year 2000 is to be approached, then the present curative hospital-based, urban-centred health service may have to give way to simpler low-cost alternatives, especially in rural areas.

Some advances have been made in developing "appropriate technology" for health care. Low-cost audiovisual aids and teaching methods for various levels of health worker have been developed under the aegis of the Indian Council of Medical Research. The Central Scientific Instruments Organization has developed a cycle-ambulance with a stretcher for the patient and a seat for the attendant; a clinical thermometer with temperature ranges indicated as coloured bands for easy use by illiterate health volunteers; a simple apparatus for vasectomy, now ready for human trial; a fetal stethoscope which can detect a fetal heart beat at week 12 of pregnancy; a miniature cardioscope and a colorimeter. The Vector Control Centre, Pondicherry, has demonstrated that certain fishes such as *Aplocheilichthys blochii* and *Gambusia affinis*, can be used as effective controls of mosquitoes, on whose larvae they feed.

For maternal and child health care by traditional birth attendants, called *dai*, a simple *dai* kit has been developed at the Postgraduate Institute of Medical Education and Research, Chandigarh. The kit should reduce the risks of tetanus, by achieving better asepsis, and helps the birth attendants to spot mothers and infants at risk — again using colour-coding principles on measuring sticks and weighing scales.

A much-needed boost to rural health care should come with the recent decision of the Indian government to set up a national committee on appropriate technology for health care. The Indian Council of Medical Research is to provide technical support for the national health programme — and at a national workshop held recently by the council the value of community health volunteers and multipurpose health workers was underlined. **Zaka Imam**

Blood products

Surplus sale

Products extracted from donations to the British National Blood Transfusion Service, and for which the National Health Service has no use, may in future be sold to pharmaceutical companies, the government has decided. Although some companies have occasionally bought products from the transfusion service in small quantities, usually for research purposes, there have been no formal arrangements for buying in bulk. Thus British companies have had to buy from

abroad.

The decision to sell off surplus blood products has emerged from a lengthy wrangle over the use of products that are now discarded, expected to be exacerbated as the transfusion service puts into operation a plan to make more blood plasma available for fractionation. There has also been a long discussion about the revamping and expansion of the Blood Products Laboratory, which carries out all fractionation of donated blood. The laboratory suffers from some of the problems of the former Lister Institute of Preventive Medicine, whose site it shares. The institute was closed in 1978 after it began to lose money and could not afford to modernize its facilities.

An earlier government suggestion that the Blood Products Laboratory be handed over to commercial management fell flat after many organizations, including blood donor groups, trades unions and Labour Members of Parliament, objected to the rise of blood donated by volunteers for overtly commercial purposes. As a compromise, the government has decided to keep the laboratory firmly under the wing of the Department of Health and to sell products surplus to the National Health Service's requirements. Any profits will be ploughed back into the health service, although it is not yet clear whether they will be spent on updating the laboratory.

The success of the scheme will depend on whether the laboratory can supply companies with products they need. Companies are negotiating with the health department, which has said only that outdated red cells and plasma fractions containing nonspecific antibodies will be available. Products for which the health service's demand exceeds supply, however, will not be for sale. They include factor 8, the blood clotting agent used for treating haemophiliacs, and albumin.

Future sales will, however, depend on the plan to make more blood plasma available for fractionation, by substituting concentrates of red cells for whole blood in transfusions and on the laboratory's ability to take on the extra work. The aim is that by the end of 1982, the laboratory will have enough plasma to produce two-fifths, compared with one-fifth at present, of the national demand for factor 8, in which it is hoped that Britain will ultimately be self-sufficient. That will mean that other products, such as factor 9, immunoglobulin and albumin, will be produced in excess and will be available for sale.

One company now discussing its needs with the Department of Health is Beechams Pharmaceuticals Limited, which would like to buy plasminogen for clinical trials in the treatment of deep-vein thrombosis. Whether the laboratory will be able and willing to supply such specific products, or will simply make certain plasma fractions available, remains to be seen. **Judy Redfearn**

Paying court

Forensic scientists in Britain are rather touchy at the moment, following the suspension of one of their number for allegedly failing to reveal crucial ambiguities in evidence on blood samples, and now the "demotion" of another for writing a research paper which is said to reveal detachment.

This second scientist resigned rather than accept a teaching post — which he regarded as demotion — and then went to an industrial tribunal to claim what he saw to be effectively unfair dismissal. However, the tribunal rejected the scientist's claim, and he is to appeal to the Employment Appeal Tribunal in London on 3 September.

His paper, which appeared in the official journal of the British Academy of Forensic Science — *Medicine, Science and the Law* — in 1977 (vol. 17 no. 1, p.37), deals with the quantitative toxicology of corpses — addressing the issue of how to estimate a drug or poison dose. The paper uses a simple law of linear diffusion to relate the drug content of various organs (taken from the data sheets of real cases) to dose and time of death as estimated by the police and witnesses. The data are clearly very scattered and the fit loose, and the author concludes "A pessimistic view is that it is impossible to remove the last vestiges of alchemy from [forensic] toxicology because of the nature of the material for analysis. It may be, apart from the fact of death, that one cannot be absolutely certain of anything and there are always contrary authorities to be found".

This conclusion may not have recommended itself to the Forensic Science Service, which as part of the Home Office runs forensic science in the United Kingdom. Other forensic scientists may equally have been unsettled.

Robert Walgate

US uranium

Falling demand

Washington

A report from the US Department of Energy (DoE) has revealed just how depressed the domestic market for uranium has become. This was already evident from the dramatic price reduction in 1980, when uranium oxide fell from \$43 to less than \$30 a pound. Now DoE has shown that, for the first time, the amount of new orders for future supplies placed by US utilities was more than outweighed by cancellations of existing commitments.

The DoE's report, *A Survey of United States Uranium Marketing Activity*, published last week, is based on information gathered from 60 utilities with nuclear reactor projects, 30 present or potential uranium users and five reactor manufacturers. It says that domestic